Wendell Industrial Co., Ltd (TPEX:6761)
Taiwan · Delayed Price · Currency is TWD 113.00
+10.00 (9.71%)
Aug 12, 2025, 1:30 PM CST
Ligand Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2020 |
| 2,077 | 2,021 | 1,743 | 1,923 | 1,894 | 1,464 | Upgrade | |
Revenue Growth (YoY) | 9.36% | 15.91% | -9.34% | 1.52% | 29.36% | 12.99% | Upgrade |
Cost of Revenue | 1,373 | 1,371 | 1,239 | 1,340 | 1,309 | 1,037 | Upgrade |
Gross Profit | 704.22 | 649.58 | 504 | 582.69 | 585.31 | 426.8 | Upgrade |
Selling, General & Admin | 382.57 | 388.37 | 339.33 | 338.54 | 329.19 | 288.27 | Upgrade |
Research & Development | 20.41 | 19.66 | 14.56 | 13.16 | 11.93 | 12.3 | Upgrade |
Operating Expenses | 403.07 | 407.99 | 356.02 | 350.58 | 341.71 | 303.31 | Upgrade |
Operating Income | 301.15 | 241.59 | 147.98 | 232.12 | 243.6 | 123.49 | Upgrade |
Interest Expense | -8.92 | -12.92 | -17.7 | -11.46 | -6 | -7.06 | Upgrade |
Interest & Investment Income | 12.55 | 15.06 | 6.76 | 2.07 | 0.38 | 0.55 | Upgrade |
Currency Exchange Gain (Loss) | 29.02 | 29.02 | -9.35 | 19.45 | -0.3 | -3 | Upgrade |
Other Non Operating Income (Expenses) | -44.38 | 1.84 | 1.73 | 7.38 | 1.51 | 1 | Upgrade |
EBT Excluding Unusual Items | 289.41 | 274.59 | 129.41 | 249.55 | 239.2 | 114.97 | Upgrade |
Gain (Loss) on Sale of Investments | -3.04 | -3.04 | 1.96 | -1.24 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.3 | -0.3 | -0.01 | -0.7 | - | - | Upgrade |
Other Unusual Items | 0 | 0 | 0.25 | 1.29 | 0.03 | 0.61 | Upgrade |
Pretax Income | 286.08 | 271.25 | 131.61 | 248.9 | 239.22 | 115.59 | Upgrade |
Income Tax Expense | 58.38 | 56.87 | 30.28 | 55.51 | 50.61 | 23.51 | Upgrade |
Earnings From Continuing Operations | 227.7 | 214.38 | 101.33 | 193.39 | 188.61 | 92.08 | Upgrade |
Net Income | 227.7 | 214.38 | 101.33 | 193.39 | 188.61 | 92.08 | Upgrade |
Net Income to Common | 227.7 | 214.38 | 101.33 | 193.39 | 188.61 | 92.08 | Upgrade |
Net Income Growth | 43.95% | 111.57% | -47.60% | 2.53% | 104.84% | 20.90% | Upgrade |
Shares Outstanding (Basic) | 32 | 30 | 25 | 25 | 23 | 23 | Upgrade |
Shares Outstanding (Diluted) | 35 | 34 | 30 | 28 | 23 | 23 | Upgrade |
Shares Change (YoY) | 11.15% | 14.89% | 8.34% | 18.62% | 1.49% | 10.25% | Upgrade |
EPS (Basic) | 7.16 | 7.25 | 4.04 | 7.70 | 8.13 | 4.03 | Upgrade |
EPS (Diluted) | 6.58 | 6.40 | 3.58 | 7.18 | 8.12 | 4.03 | Upgrade |
EPS Growth | 28.29% | 78.62% | -50.07% | -11.67% | 101.65% | 9.79% | Upgrade |
Free Cash Flow | 29.35 | 63.4 | 123.83 | -47.32 | -47.79 | 31.72 | Upgrade |
Free Cash Flow Per Share | 0.83 | 1.85 | 4.15 | -1.72 | -2.06 | 1.39 | Upgrade |
Dividend Per Share | - | 6.320 | 4.000 | 4.857 | 5.524 | 2.801 | Upgrade |
Dividend Growth | - | 58.00% | -17.65% | -12.07% | 97.20% | 26.00% | Upgrade |
Gross Margin | 33.91% | 32.14% | 28.91% | 30.30% | 30.90% | 29.15% | Upgrade |
Operating Margin | 14.50% | 11.96% | 8.49% | 12.07% | 12.86% | 8.43% | Upgrade |
Profit Margin | 10.96% | 10.61% | 5.81% | 10.06% | 9.96% | 6.29% | Upgrade |
Free Cash Flow Margin | 1.41% | 3.14% | 7.10% | -2.46% | -2.52% | 2.17% | Upgrade |
EBITDA | 324.28 | 264.79 | 177.4 | 264.6 | 272.19 | 144.35 | Upgrade |
EBITDA Margin | 15.61% | 13.10% | 10.17% | 13.76% | 14.37% | 9.86% | Upgrade |
D&A For EBITDA | 23.13 | 23.2 | 29.42 | 32.49 | 28.59 | 20.87 | Upgrade |
EBIT | 301.15 | 241.59 | 147.98 | 232.12 | 243.6 | 123.49 | Upgrade |
EBIT Margin | 14.50% | 11.96% | 8.49% | 12.07% | 12.86% | 8.43% | Upgrade |
Effective Tax Rate | 20.41% | 20.97% | 23.01% | 22.30% | 21.16% | 20.34% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.